Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie Demonstrates Progress in Oncology Research at ASCO 2016 Annual Meeting with Multiple Abstracts Evaluating Eight Medicines Across Cancer Types

[PR Newswire] – NORTH CHICAGO, Ill., May 18, 2016 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, will present data from multiple clinical trials evaluating the company’s portfolio of approved … Read more on this. AbbVie Inc. (ABBV) , with a current market cap of $97.80B, opened at $59.87. Looking at the stock, its one day range is $59.56 to $60.80 with a one year range of $45.45 to $71.60. ABBV shares are currently priced at 12.66x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 5.38x forward p/e ratio. The company pays shareholders $2.28 per share annually in dividends, yielding 3.68%. Consensus earnings for the current quarter by the 17 sell-side analysts covering the stock is an estimate of $1.20 per share, which would be $0.12 better than the year-ago quarter and a $0.04 sequential decrease. In looking at the bigger picture, the full-year EPS estimate of $4.76 would be a $0.47 improvement when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $6.21 Billion. If realized, that would be a 13.32% increase over the year-ago quarter. In terms of ratings, Societe Generale Initiated ABBV at Sell (Apr 6, 2016). Previously, Deutsche Bank Initiated ABBV at to Hold. When considering if perhaps the stock is under or overvalued, the average price target is $71.06, which is 18.69% above where the stock opened this morning. See more in (NYSE:ABBV) Similar Articles: Company Update: AbbVie Inc (NYSE:ABBV) – Bristol-Myers Squibb and AbbVie Announce European Commission Approval of Empliciti™ (elotuzumab) for the Treatment of Multiple Myeloma in Adult Patients Who Have Received at Least One Prior Therapy Market Update (NYSE:ABBV): AbbVie, University of Chicago collaborate to advance cancer research Company Update: AbbVie Inc (NYSE:ABBV) – Bristol-Myers Squibb and AbbVie Receive FDA Approval of Empliciti™ (elotuzumab) for the Treatment of Patients with Multiple Myeloma Who Have Received One to Three Prior Therapies
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.